二甲双胍与格列齐特对2型糖尿病胰岛素抵抗及脂代谢紊乱的疗效比较

Treatment of type 2 diabetic insulin resistance and fat metabolism disorder:dimethyldiguanide vs. Gliclazide capsule

目的观察比较二甲双胍与格列齐特对2型糖尿病胰岛素抵抗(IR)及脂代谢紊乱的疗效。方法将符合IR及脂代谢紊乱诊断的2型糖尿病患者56例随机分别予口服二甲双胍(A组)、格列齐特(B组)治疗3个月。结果两组治疗后胰岛素敏感性指数(ISI)较治疗前有所改善(P<0.01或0.05),组间比较差异有显著性(P<0.05)。A组甘油三酯、总胆固醇降低,高密度脂蛋白胆固醇上升(P均<0.01),体重指数下降(P<0.05),B组无明显改善(P均>0.05)。结论二甲双胍比格列齐特改善IR及血脂代谢紊乱的疗效更显著。

Objective To evaluate the clinical efficacy of dimethyldiguanide and Gliclazide capsule in treatment of type 2 diabetic insulin resistance （IR） and fat metabolism disorder. Methods 56 patients with IR and fat metabolism disorder were randomly given oral dimethyldiguanide （group A） and Glielazide capsule （group B） for 3 months. Results After treatment, the insulin sensitivity indice （ISI） in both groups were improved, compared to those before treatment （ P 〈 0.01 or 0.05）, the comparison between these two groups showed significant difference （ P 〈0.05）. An decreased triglyeeride and total cholesterol, an elevated high density lipoprotein- cholesterol were found in group A （all P 〈0.01）, and the body mass index deceased （ P 〈0.05）. All the mentioned above indice in group B were almost the same after treatment （ P 〉 0.05） Conclusion Dimethyldiguanide is more superior to Gliclazide capsule in treatment of IR and fat metabolism disorder.